gpi-1485 and Erectile-Dysfunction

gpi-1485 has been researched along with Erectile-Dysfunction* in 1 studies

Reviews

1 review(s) available for gpi-1485 and Erectile-Dysfunction

Article	Year
GPI-1485 (Guilford). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1 GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction. Topics: Administration, Oral; Animals; Antiparkinson Agents; Clinical Trials, Phase II as Topic; Erectile Dysfunction; Humans; Male; Parkinson Disease; Patents as Topic; Prostatectomy; Structure-Activity Relationship; Tacrolimus	2004

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:1

GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.

Topics: Administration, Oral; Animals; Antiparkinson Agents; Clinical Trials, Phase II as Topic; Erectile Dysfunction; Humans; Male; Parkinson Disease; Patents as Topic; Prostatectomy; Structure-Activity Relationship; Tacrolimus

2004